To include your compound in the COVID-19 Resource Center, submit it here.

Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-I trial in 311 treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax and Exviera dasabuvir with and without ribavirin for 12 weeks led to SVR4 rates

Read the full 364 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers